Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors

Bioorganic & Medicinal Chemistry Letters
2013.0

Abstract

In the present study, a small set of reversible or irreversible 4-anilinoquinazoline EGFR inhibitors was tested in A549 cells at early (1h) and late (8h) time points after inhibitor removal from culture medium. A combination of assays was employed to explain the observed long-lasting inhibition of EGFR autophosphorylation. We found that EGFR inhibition at 8h can be due, besides to the covalent interaction of the inhibitor with Cys797, as for PD168393 (2) and its prodrug 4, to the intracellular accumulation of non-covalent inhibitors by means of an active cell uptake, as for 5 and 6. Compounds 5-6 showed similar potency and duration of inhibition of EGFR autophosphorylation as the covalent inhibitor 2, while being devoid of reactive groups forming covalent bonds with protein thiols.

Knowledge Graph

Similar Paper

Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors
Bioorganic & Medicinal Chemistry Letters 2013.0
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides
Journal of Medicinal Chemistry 2012.0
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion
Journal of Medicinal Chemistry 2010.0
Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor:  4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions
Journal of Medicinal Chemistry 2000.0
Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold
Journal of Medicinal Chemistry 2018.0
Enhancement of EGFR tyrosine kinase inhibition by C–C multiple bonds-containing anilinoquinazolines
Bioorganic & Medicinal Chemistry 2010.0
Novel 4-arylaminoquinazoline derivatives with ( E )-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells
European Journal of Medicinal Chemistry 2017.0
Facile and efficient synthesis and biological evaluation of 4-anilinoquinazoline derivatives as EGFR inhibitors
Bioorganic & Medicinal Chemistry Letters 2016.0
6-Oxooxazolidine–quinazolines as noncovalent inhibitors with the potential to target mutant forms of EGFR
Bioorganic & Medicinal Chemistry 2016.0
A Chemical Tuned Strategy to Develop Novel Irreversible EGFR-TK Inhibitors with Improved Safety and Pharmacokinetic Profiles
Journal of Medicinal Chemistry 2014.0